+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID06388967

Early Detection Study of Pancreatic Cancer Using Exosome-Based MicroRNA Analysis

Led by City of Hope Medical Center · Updated on 2026-09-28

2000

Participants Needed

13

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Pancreatic ductal adenocarcinoma PDAC is a severe form of cancer that is often detected too late for effective treatment. Current blood markers like serum carbohydrate antigen 19-9 CA19-9 are unreliable for early detection. Researchers developed a method analyzing exosomes containing microRNAs miRNAs to detect early-stage PDAC more accurately. This study aims to confirm this methods effectiveness in a larger international group. The study evaluates a diagnostic test called PANcreatic cancer Exosome Early detectiON PANXEON, which uses qRT-PCR to measure levels of 5 cell-free and 8 exosome miRNAs in blood plasma. Participants include individuals diagnosed with pancreatic ductal adenocarcinoma and those without the disease, divided into training and validation groups. The study is observational and collects plasma samples to assess these miRNA signatures. Participants will provide plasma samples before any curative treatment and undergo standard diagnostic and staging procedures. Researchers will monitor outcomes including the tests sensitivity, specificity, and accuracy over about one year. The study involves individuals with various stages of PDAC and controls without the disease, with ongoing data collection until the study completion date in 2030.

CONDITIONS

Brief Title

Pancreatic Cancer Detection Consortium

Research Team

A

Ajay Goel, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here